Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Multi-340B Contract Pharmacy Locations on the Brink? The Third Circuit’s Ruling Gives a Hint.

Client Alert

Pharmacies Brace for Increased Refills Due to Coronavirus

Prelude to the Ruling

The 340B drug discount program requires pharmaceutical manufacturers to offer to sell their products at significant discounts to safety net providers called “covered entities.” In 1996, the Health Resources and Services Administration (HRSA) issued guidance authorizing covered entities to enter into a contract pharmacy arrangement with a single third-party contract pharmacy, to which the manufacturer would ship 340B medications but bill the covered entity. In 2010, HRSA issued revised guidance permitting covered entities to enter into an unlimited number of contract pharmacy arrangements.

Unhappy with growing participation in the 340B program by covered entities using multiple contract pharmacies and locations, beginning in 2020, some manufacturers began to impose distribution limitations on contract pharmacy arrangements. For example, AstraZeneca’s policy dictated that 340B pricing would not apply to drugs dispensed through contract pharmacies except for instances in which covered entities did not have their own onsite dispensing pharmacy. Sanofi and Novo Nordisk similarly sought to restrict 340B drug shipments to contract pharmacies with one exception: they agreed to ship to an unlimited number of contract pharmacies if the covered entitles furnished pharmacy claims data using their 340B ESP tools.

In May 2021, HRSA sent warning letters to these three manufacturers, forcing the manufacturers to resume shipping to all contract pharmacies or risk violating federal law. The drug manufacturers sued in response. The district courts sided with the manufacturers, ruling that HRSA could not enforce its 2010 contract pharmacy policy.

The district court rulings hinged on verbiage in Section 340B(a)(1) of the Public Health Service Act. That Section states that manufacturers that have entered into pharmaceutical pricing agreements with HHS “shall offer” covered outpatient drugs for purchase by 340B program covered entities. The manufacturers contended that “offer” meant only that 340B drugs had to be made available for purchase by a covered entity, not that they had to deliver 340B drugs wherever the covered entities requested. In contrast, the government argued that “offer” imposed a duty on manufacturers to sell the drugs to any covered entity that wished to purchase them, regardless of where the covered entities wanted the drugs shipped. The district courts agreed with the manufacturer’s definition and the government appealed to the Third Circuit.


The Third Circuit’s Ruling

On January 30, 2023, in Sanofi Aventus U.S., LLC v. HHS, the Third Circuit agreed with the district courts and ruled in favor of the drug manufacturers in a single consolidated appeal. In their ruling, the Third Circuit rejected the government’s argument that “offer” mandates that manufacturers deliver 340B drugs wherever covered entities want them delivered. Instead, while Section 340B requires manufacturers to “offer” drugs at a discounted price to covered entities, Section 340B’s text does not specify how a manufacturer should deliver the drugs. Therefore, Section 340B(a)(1) cannot be read to require manufacturers to deliver 340B drugs whenever and wherever covered entities demand—i.e., the section does not require delivery to an unlimited number of contract pharmacies.


The Impact for 340B Contract Pharmacy Programs

The practical impact of this ruling is that it permits continued manufacturer restrictions on covered entities’ use of contract pharmacies. However, the ruling is limited to the Third Circuit’s geographical reach, which includes Pennsylvania, New Jersey, and Delaware.

As of this ruling, roughly 21 drug manufacturers impose similar restrictions to AstraZeneca, Sanofi, and Novo Nordisk regarding contract pharmacy shipments. The Third Circuit ruling may incentivize more manufacturers to limit 340B shipments to only one contract pharmacy if the covered entity lacks its own pharmacy. Covered entities, in response, may struggle to provide needed services to their patients.


If you want to learn more about how the Third Circuit’s ruling may impact you as a covered entity, contact Daphne Kackloudis at or Jordan Burdick at

The NLRB Limits the Reach of Confidentiality and Non-Disparagement Provisions in Severance Agreements Overruling Trump-Era Policies

Employers should exercise caution and closely examine the content of severance agreements to ensure compliance with a recent National Labor Relations Board (“NLRB”) decision.  On February 21, 2023, the NLRB restricted the breadth of permissible language of confidentiality and non-disparagement clauses when it issued its decision in McLaren Macomb and overruled its Trump-era decisions in Baylor University Medical Center and IGT d/b/a International Game Technology.

Ohio Medical Board Releases New Telehealth Rules

On Tuesday, February 21, 2023, the State Medical Board of Ohio released its final telehealth rules to implement Ohio’s telehealth statute (O.R.C. 4743.09) for physicians, physician assistants, dieticians, respiratory care professionals and genetic counselors. Ohio’s advanced practice registered nurses (“APRNs”) should also take note of these rules. While the Medical Board does not govern APRNs directly, those APRNs who are required to have a collaborating physician and standard care arrangement (namely nurse practitioners, certified nurse midwives, and clinical nurse specialists) are still affected by the rules. Generally, if an APRN’s collaborating physician is limited in their practice, then the APRN will also be limited.

The End of the Public Health Emergency is (Finally) Here

The COVID-19 Public Health Emergency (“PHE”) that has been in effect for over three years is finally slated to end on May 11, 2023.[1] With the end of the PHE will come many changes for healthcare providers to be aware of; however, some changes may not come until much later.

Five Opportunities for Operations and Compliance Excellence in 2023

With the holidays behind us and the rest of the year ahead, now is the perfect time to get your operational/compliance house in order! Though your list might be a mile (or an inch) long, here are five places to start.

The Pregnant Workers Fairness Act - What Employers Need to Know

Effective June 27, 2023, the Pregnant Workers Fairness Act (PWFA) will require employers with at least 15 employees to provide reasonable accommodations for qualified employees with pregnancy-related restrictions unless doing so would impose an undue hardship on the employer.